Wechselwirkungen · Xeloda
Xeloda 150 mg film-coated tablets. Xeloda 500 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 10
HOS-091418 · Präparat HOS-084311
Brivudine: a clinically significant interaction between brivudine and fluoropyrimidines (e.g. capecitabine, 5-Fluorouracil, tegafur), resulting from the inhibition of dihydropyrimidine dehydrogenase by brivudine, has been described. This interaction, which leads to increased fluoropyrimidine toxicity, is potentially fatal. Therefore, brivudine must not be administered concomitantly with capecitabine (see section 4.3 and 4.4). There must be at least a 4-week waiting period between end of treatment with brivudine and start of capecitabine therapy. Treatment with brivudine can be started 24 hours after the last dose of capecitabine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fluorouracil (HOS-086023) tegafur (HOS-091419) brivudine (HOS-091415)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-02T14:45:00Z · SHA-256 632b962270222a1b1c9626101f7ef2fdc0c5500039de7f68bd6fd6e7e22b7b52 · Passage 0173893da4d7891fcb9e8eb33bd0953e209988b23360df75e86147d8075c9f0a · Zeichen 100–737 im Abschnitt